Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.3%

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was down 3.3% on Tuesday . The stock traded as low as $9.64 and last traded at $9.67. Approximately 22,270 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 348,044 shares. The stock had previously closed at $10.00.

Analysts Set New Price Targets

Separately, BMO Capital Markets restated an "outperform" rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Centessa Pharmaceuticals Trading Down 6.0 %

The business's 50 day simple moving average is $10.95 and its 200 day simple moving average is $8.50. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.00 and a quick ratio of 8.00. The stock has a market cap of $942.91 million, a P/E ratio of -5.99 and a beta of 1.38.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The firm had revenue of $6.85 million during the quarter. On average, analysts expect that Centessa Pharmaceuticals plc will post -1.83 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Karen M. Anderson sold 51,160 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the sale, the insider now owns 71,525 shares of the company's stock, valued at $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Karen M. Anderson sold 51,160 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the sale, the insider now owns 71,525 shares of the company's stock, valued at $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Harris Rotman sold 4,267 shares of the firm's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.10, for a total transaction of $34,562.70. Following the completion of the sale, the senior vice president now directly owns 62,625 shares of the company's stock, valued at approximately $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is currently owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of CNTA. Adage Capital Partners GP L.L.C. grew its holdings in Centessa Pharmaceuticals by 25.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company's stock worth $18,313,000 after acquiring an additional 580,500 shares during the period. Octagon Capital Advisors LP grew its holdings in Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company's stock worth $16,398,000 after acquiring an additional 1,584,500 shares during the period. Franklin Resources Inc. grew its holdings in Centessa Pharmaceuticals by 34.1% during the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company's stock worth $8,882,000 after acquiring an additional 283,469 shares during the period. Affinity Asset Advisors LLC grew its holdings in Centessa Pharmaceuticals by 13.0% during the 3rd quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company's stock worth $6,587,000 after acquiring an additional 117,368 shares during the period. Finally, Platinum Investment Management Ltd. grew its holdings in Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company's stock worth $3,033,000 after acquiring an additional 43,539 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.